Patients with unexplained physical symptoms have poorer quality of life and higher costs than other patient groups: a cross-sectional study on burden

BMC Health Services Research

Jan JV Busschbach³  Adriaan van ’t Spijker³  Cornelis G Kooiman¹  Mirjam AG Sprangers²  Lyonne NL Zonneveld² 

[1] Department of Psychotherapy, Riagg Rijnmond, Stationsplein 2, 3112, HJ Schiedam, The Netherlands;Department of Medical Psychology, Academic Medical Center, University of Amsterdam, PO Box 22660, 1100, DD Amsterdam, The Netherlands;Department of Psychiatry, Section Medical Psychology and Psychotherapy, Erasmus Medical Center, PO Box 2040, 3000, CA Rotterdam, The Netherlands

关键词: Unexplained physical symptoms;    Somatoform disorder;    Somatic symptom disorder;    Quality of life;    Production loss;    Presenteeism;    Healthcare utilization;    Costs;    Chronic disease;    Burden;    Absenteeism;   

Others  :  1134472
DOI  :  10.1186/1472-6963-13-520

 received in 2013-04-22, accepted in 2013-12-09,  发布年份 2013

【 摘 要 】

Background

To determine whether healthcare resources are allocated fairly, it is helpful to have information on the quality of life (QoL) of patients with Unexplained Physical Symptoms (UPS) and on the costs associated with them, and on how these relate to corresponding data in other patient groups. As studies to date have been limited to specific patient populations with UPS, the objective of this study was to assess QoL and costs in a general sample of patients with UPS using generic measures.

Methods

In a cross-sectional study, 162 patients with UPS reported on their QoL, use of healthcare resources and lost productivity in paid and unpaid work. To assess QoL, the generic SF-36 questionnaire was used, from which multidimensional quality-of-life scores and a one-dimensional score (utility) using the SF-6D scorings algorithm were derived. To assess costs, the TiC-P questionnaire was used.

Results

Patients with UPS reported a poor QoL. Their QoL was mostly decreased by limitations in functioning due to physical health, and the least by limitations in functioning due to emotional problems. The median of utilities was 0.57, and the mean was 0.58 (SD = .09).

The cost for the use of healthcare services was estimated to be €3,123 (SD = €2,952) per patient per year. This cost was enlarged by work-related costs: absence from work (absenteeism), lower on-the-job productivity (presenteeism), and paid substitution of domestic tasks. The resulting mean total cost was estimated to be €6,815 per patient per year.

Conclusions

These findings suggest that patients with UPS have a high burden of disease and use a considerable amount of healthcare resources. In comparison with other patient groups, the QoL values of patients with UPS were among the poorest and their costs were among the highest of all patient groups. The burden for both patients and society helps to justify the allocation of sufficient resources to effective treatment for patients with UPS.

Trial registration

Nederlands Trial Register, NTR1609

【 授权许可】

   
2013 Zonneveld et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Kroenke K: Patients presenting with somatic complaints: epidemiology, psychiatric co-morbidity and management. Int J Methods Psychiatr Res 2003, 12(1):34-43.
• [2]Nimnuan C, Hotopf M, Wessely S: Medically unexplained symptoms: an epidemiological study in seven specialities. J Psychosom Res 2001, 51(1):361-367.
• [3]Kooiman CG, Bolk JH, Brand R, Trijsburg RW, Rooijmans HG: Is alexithymia a risk factor for unexplained physical symptoms in general medical outpatients? Psychosom Med 2000, 62(6):768-778.
• [4]Grandes G, Montoya I, Arietaleanizbeaskoa MS, Arce V, Sanchez A: The burden of mental disorders in primary care. European Psychiatry 2011, 26(7):428-435.
• [5]Koch H, Van Bokhoven MA, Ter Riet G, Van der Weijden T, Dinant GJ, Bindels PJE: Demographic characteristics and quality of life of patients with unexplained complaints: a descriptive study in general practice. Qual Life Res 2007, 16(9):1483-1489.
• [6]Löwe B, Spitzer RL, Williams JBW, Mussell M, Schellberg D, Kroenke K: Depression, anxiety and somatization in primary care: syndrome overlap and functional impairment. Gen Hosp Psychiatry 2008, 30(3):191-199.
• [7]De Waal MWM, Arnold IA, Eekhof JAH, Van Hemert AM: Somatoform disorders in general practice: prevalence, functional impairment and comorbidity with anxiety and depressive disorders. Br J Psychiatry 2004, 184(6):470-476.
• [8]Verhaak PFM, Meijer SA, Visser AP, Wolters G: Persistent presentation of medically unexplained symptoms in general practice. Fam Pract 2006, 23(4):414-420.
• [9]Smith GR, Monson RA, Ray DC: Patients with multiple unexplained symptoms: their characteristics, functional health, and health care utilization. Arch Intern Med 1986, 146(1):69-72.
• [10]Barsky AJ, Orav EJ, Bates DW: Somatization increases medical utilization and costs independent of psychiatric and medical comorbidity. Arch Gen Psychiatry 2005, 62(8):903-910.
• [11]Reynolds KJ, Vernon SD, Bouchery E, Reeves WC: The economic impact of chronic fatigue syndrome. Cost Effectiveness and Resource Allocation 2004, 2(1):4. BioMed Central Full Text
• [12]Stolk EA, Van Donselaar G, Brouwer WBF, Busschbach JJV: Reconciliation of economic concerns and health policy: illustration of an equity adjustment procedure using proportional shortfall. Pharmacoeconomics 2004, 22(17):1097-1107.
• [13]Stolk EA, Pickee SJ, Ament AHJA, Busschbach JJV: Equity in health care prioritisation: an empirical inquiry into social value. Health Policy 2005, 74(3):343-355.
• [14]Busschbach JJV, McDonnell J, Essink-Bot M-L, Van Hout BA: Estimating parametric relationships between health description and health valuation with an application to the EuroQol EQ-5D. J Health Econ 1999, 18(5):551-571.
• [15]Brazier J, Roberts J, Tsuchiya A, Busschbach J: A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ 2004, 13(9):873-884.
• [16]Moock J, Kohlmann T: Comparing preference-based quality-of-life measures: results from rehabilitation patients with musculoskeletal, cardiovascular, or psychosomatic disorders. Qual Life Res 2008, 17(3):485-495.
• [17]Paterson C, Taylor RS, Griffiths P, Britten N, Rugg S, Bridges J, McCallum B, Kite G: Acupuncture for ‘frequent attenders’ with medically unexplained symptoms: a randomised controlled trial (CACTUS study). Br J Gen Pract 2011, 61(587):e295-e305.
• [18]Zonneveld LNL, Van Rood YR, Timman R, Kooiman CG, Van ’t Spijker A, Busschbach JJV: Effective group training for patients with unexplained physical symptoms: a randomized controlled trial with a non-randomized one-year follow-up. PLoS ONE 2012, 7(8):e42629.
• [19]Zonneveld LNL, Van't Spijker A, Passchier J, Van Busschbach JJ, Duivenvoorden HJ: The effectiveness of a training for patients with unexplained physical symptoms: protocol of a cognitive behavioral group training and randomized controlled trial. BMC Public Health 2009, 9:251. BioMed Central Full Text
• [20]First MB, Spitzer RL, Gibbon M, Williams JBW: Structured clinical interview for DSM-IV axis I disorders. Amsterdam: Harcourt Test Publishers; 1999.
• [21]Ware JE, Snow KK, Kosinski M, Gandek B: SF-36 health survey: manual and interpretation guide. Boston, MA: New England Medical Center, The Health Institute; 1993.
• [22]Aaronson NK, Muller M, Cohen PDA, Essink-Bot M, Fekkes M, Sanderman R, Sprangers MAG, Te Velde AM, Verrips E: Translation, validation and norming of the Dutch language version of the SF-36 health survey in community and chronic disease populations. J Clin Epidemiol 1998, 51(11):1055-1068.
• [23]Brazier J, Roberts J, Deverill M: The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002, 21(2):271-292.
• [24]Hakkaart-van Roijen L: Handleiding Trimbos/iMTA questionnaire for costs associated with psychiatric Illness (TiC-P). In juli 2002 edn. Rotterdam: Institute for Medical Technology Assessment & Erasmus Universiteit Rotterdam; 2002.
• [25]Hakkaart-van Roijen L, Tan SS, Bouwmans CAM: Handleiding voor kostenonderzoek, methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg, Geactualiseerde versie 2010 edn. Diemen: College voor Zorgverzekeringen; 2010.
• [26]Hakkaart-van Roijen L, Van Straten A, Donker M, Tiemens B: Handleiding Trimbos/iMTA questionnaire for costs associated with psychiatric illness (TiC-P). Rotterdam: Instituut voor Medische Technology Assessment, Erasmus Universiteit Rotterdam; 2010.
• [27]Group training for patients with unexplained physical symptoms http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=1609 webcite
• [28]Statistics N: Consumentenprijzen; prijsindex 2006 = 100 (CPI 2009). In vol. 2012. Den Haag/Heerlen: Statistics Netherlands/Centraal Bureau voor de Statistiek; 2012.
• [29]Statistics N: Consumentenprijzen; prijsindex 2006 = 100 (CPI 2007). In vol. 2012. Den Haag/Heerlen: Statistics Netherlands/Centraal Bureau voor de Statistiek; 2012.
• [30]Brouwer WBF, Koopmanschap MA, Rutten FFH: Productivity losses without absence: measurement validation and empirical evidence. Health Policy 1999, 48(1):13-27.
• [31]Statistics N: Cao-lonen, contractuele loonkosten en arbeidsduur; indexcijfers (2000 = 100). In., vol. 2012. Den Haag/Heerlen: Statistics Netherlands/Centraal Bureau voor de Statistiek; 2012.
• [32]Smith RC, Gardiner JC, Lyles JS, Sirbu C, Dwamena FC, Hodges A, Collins C, Lein C, Given CW, Given B, et al.: Exploration of DSM-IV criteria in primary care patients with medically unexplained symptoms. Psychosom Med 2005, 67(1):123-129.
• [33]Kruijshaar ME, Hoeymans N, Bijl RV, Spijker J, Essink-Bot ML: Levels of disability in major depression: findings from the Netherlands mental health survey and incidence study (NEMESIS). J Affect Disord 2003, 77(1):53-64.
• [34]Osoba D: Interpreting the meaningfulness of changes in health-related quality of life scores: lessons from studies in adults. Int J Cancer 1999, 83(S12):132-137.
• [35]Jaeschke R, Singer J, Guyatt GH: Measurement of health status: ascertaining the minimal clinically important difference. Control Clin Trials 1989, 10(4):407-415.
• [36]Kontodimopoulos N, Pappa E, Papadopoulos AA, Tountas Y, Niakas D: Comparing SF-6D and EQ-5D utilities across groups differing in health status. Qual Life Res 2009, 18(1):87-97.
• [37]Fernández A, Saameño JÁB, Pinto-Meza A, Luciano JV, Autonell J, Palao D, Salvador-Carulla L, Campayo JG, Haro JM, Serrano A: Burden of chronic physical conditions and mental disorders in primary care. Br J Psychiatry 2010, 196(4):302-309.
• [38]Teckle P, Peacock S, McTaggart-Cowan H, Van der Hoek K, Chia S, Melosky B, Gelmon K: The ability of cancer-specific and generic preference-based instruments to discriminate across clinical and self-reported measures of cancer severities. Health Qual Life Outcomes 2011, 9:106. BioMed Central Full Text
• [39]Kontodimopoulos N, Aletras VH, Paliouras D, Niakas D: Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments. Value in Health 2009, 12(8):1151-1157.
• [40]Walters SJ, Brazier JE: Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res 2005, 14(6):1523-1532.
• [41]Slobbe LCJ, Smit JM, Groen J, Poos MJJC, Kommer GJ: Kosten van ziekten in Nederland 2007: trends in de Nederlandse zorguitgaven 1999–2010. In Zorg voor euro's. Bilthoven: Rijksinstituut voor Volksgezondheid en Milieu (RIVM)/Centraal Bureau voor de Statistiek (CBS); 2011. RIVM-rapportnummer 270751023/270752011
• [42]Klein Hesselink J, Hooftman W, Koppes L: Ziekteverzuim in Nederland in 2010. Hoofddorp: TNO; 2012.
• [43]Hakkaart-van Roijen L, Hoeijenbos MB, Regeer EJ, Ten Have M, Nolen WA, Veraart CPWM, Rutten FFH: The societal costs and quality of life of patients suffering from bipolar disorder in the Netherlands. Acta Psychiatr Scand 2004, 110(5):383-392.
• [44]Soeteman DI, Hakkaart-van Roijen L, Verheul R, Busschbach JJV: The economic burden of personality disorders in mental health care. J Clin Psychiatry 2008, 69(2):259-265.
• [45]Gr J-G: Beperkt aan het werk: rapportage ziekteverzuim, arbeidsongeschiktheid en arbeidsparticipatie. Den Haag: Sociaal en Cultureel Planbureau; 2010.
• [46]Braakman-Jansen LMA, Taal E, Kuper IH, Van de Laar MAFJ: Productivity loss due to absenteeism and presenteeism by different instruments in patients with RA and subjects without RA. Rheumatology (Oxford) 2012, 51(2):354-361.
• [47]Smit F, Cuijpers P, Oostenbrink J, Batelaan N, De Graaf R, Beekman A: Costs of nine common mental disorders: implications for curative and preventive psychiatry. J Ment Health Policy Econ 2006, 9(4):193-200.
• [48]Kroenke K: Efficacy of treatment for somatoform disorders: a review of randomized controlled trials. Psychosom Med 2007, 69(9):881-888.
• [49]Noyes R, Langbehn DR, Happel RL, Stout LR, Muller BA, Longley SL: Personality dysfunction among somatizing patients. Psychosomatics 2001, 42(4):320-329.
• [50]Garyfallos G, Adamopoulou A, Karastergiou A, Voikli M, Ikonomidis N, Donias S, Giouzepas J, Dimitriou E: Somatoform disorders: comorbidity with other DSM-III-R psychiatric diagnoses in Greece. Compr Psychiatry 1999, 40(4):299-307.
• [51]Leibbrand R, Hiller W, Fichter MM: Effect of comorbid anxiety, depressive, and personality disorders on treatment outcome of somatoform disorders. Compr Psychiatry 1999, 40(3):203-209.
• [52]Katon WJ, Ries RK, Kleinman A: Part II: a prospective DSM-III study of 100 consecutive somatization patients. Compr Psychiatry 1984, 25(3):305-314.
• [53]Uguz F, Engin B, Yilmaz E: Axis I and Axis II diagnoses in patients with chronic idiopathic urticaria. J Psychosom Res 2008, 64(2):225-229.
• [54]Garcia-Campayo J, Alda M, Sobradiel N, Olivan B, Pascual A: Personality disorders in somatization disorder patients: a controlled study in Spain. J Psychosom Res 2007, 62(6):675-680.
• [55]Maina G, Albert U, Gandolfo S, Vitalucci A, Bogetto F: Personality disorders in patients with burning mouth syndrome. J Personal Disord 2005, 19(1):84-93.
• [56]Henderson M, Tannock C: Objective assessment of personality disorder in chronic fatigue syndrome. J Psychosom Res 2004, 56(2):251-254.
• [57]Dammen T, Ekeberg Ø, Arnesen H, Friis S: Personality profiles in patients referred for chest pain: investigation with emphasis on panic disorder patients. Psychosomatics 2000, 41(3):269-276.
• [58]Rost KM, Akins RN, Brown FW, Smith GR: The comorbidity of DSM-III-R personality disorders in somatization disorder. Gen Hosp Psychiatry 1992, 14(5):322-326.
• [59]Sprangers MAG, De Regt EB, Andries F, Van Agt HME, Bijl RV, De Boer JB, Foets M, Hoeymans N, Jacobs AE, Kempen GIJM, et al.: Which chronic conditions are associated with better or poorer quality of life? J Clin Epidemiol 2000, 53(9):895-907.
• [60]Henningsen P, Zimmermann T, Sattel H: Medically unexplained physical symptoms, anxiety, and depression: a meta-analytic review. Psychosom Med 2003, 65(4):528-533.
• [61]Evans CJ: Health and work productivity assessment: state of the art or state of flux? J Occup Environ Med 2004, 46(6):S3-S11.
• [62]Osterhaus JT, Gutterman DL, Plachetka JR: Healthcare resource and lost labor costs of migraine headache in the US. Pharmacoeconomics 1992, 2(1):67-76.
• [63]Nezu AM, Nezu CM, Lombardo ER: Cognitive-behavior therapy for medically unexplained symptoms: a critical review of the treatment literature. Behavior Therapy 2001, 32(3):537-583.
• [64]Sumathipala A: What is the evidence for the efficacy of treatments for somatoform disorders? A critical review of previous intervention studies. Psychosom Med 2007, 69(9):889-900.
• [65]Sumathipala A, Siribaddana S, Abeysingha MRN, De Silva P, Dewey M, Prince M, Mann AH: Cognitive behavioural therapy v. structured care for medically unexplained symptoms: randomised controlled trial. Br J Psychiatry 2008, 193(1):51-59.
• [66]Morriss R, Dowrick C, Salmon P, Peters S, Dunn G, Rogers A, Lewis B, Charles-Jones H, Hogg J, Clifford R, et al.: Cluster randomised controlled trial of training practices in reattribution for medically unexplained symptoms. Br J Psychiatry 2007, 191(6):536-542.
• [67]Aiarzaguena JM, Grandes G, Gaminde I, Salazar A, Sánchez Á, Ariño J: A randomized controlled clinical trial of a psychosocial and communication intervention carried out by GPs for patients with medically unexplained symptoms. Psychol Med 2007, 37(2):283-294.
• [68]Toft T, Rosendal M, Ørnbøl E, Olesen F, Frostholm L, Fink P: Training general practitioners in the treatment of functional somatic symptoms: effects on patient health in a cluster-randomised controlled trial (the Functional Illness in Primary Care Study). Psychother Psychosom 2010, 79(4):227-237.
• [69]Arnold IA, De Waal MWM, Eekhof JAH, Assendelft WJJ, Spinhoven P, Van Hemert AM: Medically unexplained physical symptoms in primary care: a controlled study on the effectiveness of cognitive-behavioral treatment by the family physician. Psychosomatics 2009, 50(5):515-524.
• [70]Rosendal M, Olesen F, Fink P, Toft T, Sokolowski I, Bro F: A randomized controlled trial of brief training in the assessment and treatment of somatization in primary care: effects on patient outcome. Gen Hosp Psychiatry 2007, 29(4):364-373.